Identification of Cell-Surface Proteins Endocytosed by Human Brain Microvascular Endothelial Cells In Vitro.
blood–brain barrier
cell-surface biotinylation
internalization
podocalyxin
proteomics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
30
04
2020
revised:
15
06
2020
accepted:
18
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
27
6
2020
Statut:
epublish
Résumé
Cell-surface proteins that can endocytose into brain microvascular endothelial cells serve as promising candidates for receptor-mediated transcytosis across the blood-brain barrier (BBB). Here, we comprehensively screened endocytic cell-surface proteins in hCMEC/D3 cells, a model of human brain microvascular endothelial cells, using surface biotinylation methodology and sequential window acquisition of all theoretical fragment-ion spectra-mass spectrometry (SWATH-MS)-based quantitative proteomics. Using this method, we identified 125 endocytic cell-surface proteins from hCMEC/D3 cells. Of these, 34 cell-surface proteins were selectively internalized into human brain microvascular endothelial cells, but not into human umbilical vein endothelial cells (HUVECs), a model of human peripheral microvascular endothelial cells. Two cell-surface proteins, intercellular adhesion molecule-1 (ICAM1) and podocalyxin (PODXL), were identified as BBB-localized endocytic cell-surface proteins in humans, using open mRNA and protein databases. Immunohistochemical evaluation confirmed PODXL expression in the plasma membrane of hCMEC/D3 cells and revealed that anti-PODXL antibody-labeled cell-surface PODXL internalized into hCMEC/D3 cells. Immunohistochemistry further revealed that PODXL is localized at the luminal side of human brain microvessels, supporting its potential suitability for translational applications. In conclusion, our findings highlight novel endocytic cell-surface proteins capable of internalizing into human brain microvascular endothelial cells. ICAM1 or PODXL targeted antibody or ligand-labeled biopharmaceuticals and nanocarriers may provide effective targeted delivery to the brain across the BBB for the treatment of central nervous system (CNS) diseases.
Identifiants
pubmed: 32585920
pii: pharmaceutics12060579
doi: 10.3390/pharmaceutics12060579
pmc: PMC7356521
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science
ID : 15H01562
Organisme : Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science
ID : 18H02590
Organisme : Japan Science and Technology Agency (JST)-CREST
ID : JP171024167
Organisme : The Mochida Memorial Foundation for Medical and Pharmaceutical Research
ID : 2019
Références
Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12
pubmed: 23636093
J Neuroimmunol. 1992 Jul;39(1-2):11-21
pubmed: 1352310
J Control Release. 2012 Oct 10;163(1):25-33
pubmed: 22698938
Nature. 1989 May 4;339(6219):61-4
pubmed: 2497351
Elife. 2014 Sep 17;3:e03970
pubmed: 25232658
J Neuropathol Exp Neurol. 2002 Jul;61(7):585-96
pubmed: 12125737
Nat Immunol. 2007 Sep;8(9):913-9
pubmed: 17712344
Am J Physiol Cell Physiol. 2009 Mar;296(3):C505-13
pubmed: 19118161
J Neurosci Res. 1987;18(2):299-304
pubmed: 3694713
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Methods Enzymol. 2012;503:269-92
pubmed: 22230573
J Neurosci Res. 1992 Feb;31(2):365-74
pubmed: 1374132
J Neurooncol. 2019 Aug;144(1):21-32
pubmed: 31147892
Mol Pharm. 2019 May 6;16(5):2162-2171
pubmed: 30983357
J Control Release. 2020 May 7;324:181-193
pubmed: 32389778
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
Pharm Res. 2014 Jul;31(7):1855-66
pubmed: 24558007
Mol Ther. 2019 Feb 6;27(2):456-464
pubmed: 30595526
Proteomics. 2016 Aug;16(15-16):2106-17
pubmed: 27197958
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
PLoS One. 2010 Nov 30;5(11):e14157
pubmed: 21152401
J Pharmacol Exp Ther. 2000 Mar;292(3):1048-52
pubmed: 10688622
Mol Pharm. 2013 Jan 7;10(1):289-96
pubmed: 23137377
Trends Immunol. 2012 Dec;33(12):579-89
pubmed: 22926201
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Small GTPases. 2016 Oct;7(4):231-238
pubmed: 27463697
Cell Tissue Res. 1999 Jan;295(1):77-88
pubmed: 9931355
J Neurosci Res. 2000 Mar 15;59(6):722-30
pubmed: 10700009
J Neurochem. 2010 Feb;112(3):625-35
pubmed: 19895664
J Clin Invest. 1996 Jan 1;97(1):209-16
pubmed: 8550836
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
J Pharm Sci. 2018 Dec;107(12):3163-3170
pubmed: 30145211
Biol Pharm Bull. 2019;42(6):944-953
pubmed: 31155591
Blood. 2005 Jul 15;106(2):584-92
pubmed: 15811956
Brain Pathol. 1995 Oct;5(4):339-44
pubmed: 8974619
J Cell Sci. 2003 Apr 15;116(Pt 8):1599-609
pubmed: 12640043
Nat Commun. 2017 Oct 17;8(1):1001
pubmed: 29042554
J Cell Biol. 2011 Apr 4;193(1):61-70
pubmed: 21464228
Mol Pharm. 2019 Jan 7;16(1):292-304
pubmed: 30452273
J Proteome Res. 2008 Feb;7(2):731-40
pubmed: 18183947
Neuron. 2016 Jan 6;89(1):70-82
pubmed: 26687840
J Alzheimers Dis. 2014;38(1):185-200
pubmed: 23948938
J Neurochem. 2008 Aug;106(4):1534-44
pubmed: 18489712
Proteomics. 2014 Mar;14(6):659-67
pubmed: 24449390
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4771-5
pubmed: 2052557
J Proteome Res. 2016 Feb 5;15(2):647-58
pubmed: 26699813
Mol Ther. 2018 May 2;26(5):1366-1374
pubmed: 29606503
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
J Cell Biol. 2004 Oct 25;167(2):377-88
pubmed: 15504916